Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Gossamer Bio Inc

GOSS ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.15

▼ -1.78%

Market Cap $75.62M · Vol 9.01M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$75.62M

Micro Cap

Div Yield

N/A

EPS Growth

+55.51%

YoY

RSI (14)

38.55

Momentum

Beta

2.00

vs Market

52W High

$3.87

96.00% below

52W Low

$0.11

34.76% above

Volume

9.01M

Avg 3.12M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

98.48%

Public shares

Shariah Compliance8 STANDARDS

✗ Gossamer Bio Inc (GOSS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GOSS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.32%

-0.06%

-23.00%

-92.74%

YTD

-95.01%

-92.87%

-84.98%

-98.26%

Financials & Valuation

TTM · Annual

Total Revenue	$48.47M
Net Income	$-170,370,000.00
Revenue Growth (YoY)	-19.59%
Gross Margin	100.00%
Operating Margin	-336.81%
Net Profit Margin	-351.49%
ROE	N/A
ROA · ROIC	-69.93% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	14.62
P/B	N/A
P/FCF	N/A
EPS Growth	+55.51%
Outstanding Shares	488.85M

Technical Indicators

50-Day SMA	$0.17
200-Day SMA	$1.22
RSI (14)	38.55
Beta	2.00
52-Week High	$3.87
52-Week Low	$0.11

Volume Today	9.01M
Avg Daily Volume (30D)	3.12M
Relative Volume	2.88x
Volatility (10D)	86.06
Volatility (30D)	160.18
Free Float	98.48%

Analyst Consensus

BUY

Current Price $0.15

Mean Target $2.88

52W Low$0.11 52W High$3.87

Current

Target

$0.11 $3.87

Current Analyst target

+1,761.67% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00MVWLMC1

ISINUS38341P1021

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.09% ONC BeOne Medicines AG +1.44% RVMD Revolution Medicines Inc -1.07% 068270.KS Celltrion Inc -0.93% ABVX Abivax SA -2.75%

Company Profile

Gossamer Bio, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The Company's lead product candidate is Seralutinib (GB002), is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR. Seralutinib is designed to inhibit multiple kinases in the pathology of PAH. The PDGFR is a tyrosine kinase receptor which, when activated by its agonist, induces cellular proliferation. The c-KIT pathway was also identified as a factor involved in pulmonary vascular remodeling, particularly in the cells implicated in perivascular inflammation.